Bioventus (BVS) vs InMode (INMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bioventus (BVS) has outperformed InMode (INMD) over the past year, gaining 92.0% versus a loss of 6.8%. Over five years, BVS leads with a -6.4% price change compared with -83.2% for INMD. Bioventus is the larger company by market cap ($866.8 million vs $810.2 million), about 1.1 times the size.
On valuation, InMode trades at a lower forward P/E (10.3x vs 13.8x for Bioventus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | INMD |
|---|---|---|
| Share price | $12.69 | $14.08 |
| Market cap | $866.79M | $810.22M |
| 1-day change | -0.63% | +0.50% |
| YTD return | +71.64% | -4.63% |
| 1-year return | +92.03% | -6.79% |
| 5-year return | -6.38% | -83.20% |
| P/E ratio (TTM) | 16.27 | 11.64 |
| Forward P/E | 13.79 | 10.26 |
| EPS (TTM) | $0.78 | $1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $16.74 |
| 52-week low | $6.37 | $12.72 |
| Distance from 52-week high | -20.15% | -15.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +38.69% | +14.84% |
| Average volume | 619.63K | 521.98K |
| Shares outstanding | 68.31M | 57.54M |
| Employees | 950 | 660 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed INMD by 98.8 percentage points over the past year.
- Bioventus trades at a higher earnings multiple (16.3x vs 11.6x trailing P/E).
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 950 employees
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
BVS vs INMD FAQ
Which is bigger, Bioventus or InMode?
Bioventus (BVS) is larger, with a market capitalization of $866.79M compared with $810.22M for InMode (INMD).
Which stock has performed better over the past year, BVS or INMD?
BVS returned +92.03% over the past 12 months, compared with -6.79% for INMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BVS or INMD?
INMD has the lower trailing P/E at 11.6, versus 16.3 for BVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bioventus and InMode in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Bioventus and Biotechnology: Electromedical & Electrotherapeutic Apparatus for InMode.